Cabozantinib
Kinase Inhibitor — ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
Also known as: cabometyx, cabozantinib (S)-malate, cabozantinib malate, cabozantinib S-malate, cometriq, XL184
Data last refreshed: (DrugCentral release 2024-11-01)
Key facts
Cabozantinib is an onp drug in the Kinase Inhibitor class catalogued in DrugCentral. It was first approved by the FDA in 2012. Its mechanism of action is classified as Protein Kinase Inhibitors. DrugCentral lists 34 molecular targets, including KDR, MERTK and SLTM. Recorded indications include Liver cell carcinoma, Medullary thyroid carcinoma, Metastatic renal cell carcinoma and Renal cell carcinoma.
- Approval status: onp (first approved 2012 by the FDA).
- Drug class: Kinase Inhibitor.
- Mechanism of action: Protein Kinase Inhibitors.
- Molecular targets: KDR, MERTK, SLTM and MET (34 listed in DrugCentral).
- Indications: Liver cell carcinoma, Medullary thyroid carcinoma, Metastatic renal cell carcinoma and Renal cell carcinoma.
- ATC code: L01EX07 (Other protein kinase inhibitors).
- Molecular formula: C28H24FN3O5; molecular weight 501.51 g/mol.
Indications & contraindications
Drug–disease relationships curated by DrugCentral (OMOP / SNOMED concepts).
Indications (4)
- Liver cell carcinoma
- Medullary thyroid carcinoma
- Metastatic renal cell carcinoma
- Renal cell carcinoma
Mechanism & targets
| Mechanism of action (MoA) | Protein Kinase Inhibitors |
|---|---|
| Established pharmacologic class | Kinase Inhibitor |
Molecular targets (34)
Regulatory approvals (3)
| Date | Agency | Marketed as | Applicant | Orphan |
|---|---|---|---|---|
| 2020-03-25 | PMDA | — | Takeda Pharmaceutical Company Limited | |
| 2014-03-21 | EMA | — | TMC Pharma Services Ltd | Yes |
| 2012-11-29 | FDA | — | EXELIXIS | Yes |
ATC classification
| ATC code | Therapeutic hierarchy |
|---|---|
L01EX07 | ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS › ANTINEOPLASTIC AGENTS › PROTEIN KINASE INHIBITORS › Other protein kinase inhibitors |
Pharmacogenomics
Drug-label and guideline annotations from PharmGKB and CPIC.
- FDA label: RET
Reported adverse-event signals
Strongest FDA FAERS disproportionality signals (log-likelihood ratio). A signal is a statistical association in spontaneous reports, not proof that the drug causes the event.
| MedDRA term | LLR |
|---|---|
| Palmar-plantar erythrodysaesthesia syndrome | 6254.6 |
| Malignant neoplasm progression | 4111.4 |
| Hepatic function abnormal | 2111.2 |
| Diarrhoea | 1998.1 |
| Off label use | 1635.1 |
| Hypothyroidism | 1558.1 |
| Decreased appetite | 1222.2 |
| Proteinuria | 956.8 |
| Hypertension | 768.9 |
| Taste disorder | 747.5 |
| Stomatitis | 602.1 |
| Hair colour changes | 601.8 |
Chemical structure
Full physicochemical, ADMET and 3D-structure analysis of Cabozantinib is on its molecule page.
| Molecular formula | C28H24FN3O5 |
|---|---|
| Molecular weight | 501.51 g/mol |
| CAS number | 849217-68-1 |
| InChIKey | ONIQOQHATWINJY-UHFFFAOYSA-N |
| PubChem CID | 25102847 |
Frequently asked questions
Answers are generated from the structured data on this page, not written by hand.
What is Cabozantinib used for?
DrugCentral lists the following indications for Cabozantinib: Liver cell carcinoma, Medullary thyroid carcinoma, Metastatic renal cell carcinoma and Renal cell carcinoma.
How does Cabozantinib work?
Cabozantinib is classified as Protein Kinase Inhibitors; its molecular targets in DrugCentral include KDR (inhibitor), MERTK, SLTM and MET (inhibitor).
When was Cabozantinib first approved?
Cabozantinib was first approved by the FDA in 2012.
What drug class does Cabozantinib belong to?
Cabozantinib is in the Kinase Inhibitor class.
What is the chemical formula of Cabozantinib?
Cabozantinib has the molecular formula C28H24FN3O5 and a molecular weight of 501.51 g/mol.
Browse: all drugs starting with C · drug guides by category · protein targets A–Z.
Sources
- DrugCentral drug card 4715 — structure, indications, targets, approvals, pharmacologic classes (CC BY-SA 4.0)
- ChEMBL CHEMBL2103868 — compound record and bioactivity
- PubChem CID 25102847 — chemical identifiers
- DrugBank DB08875 — drug record
- FDA UNII 1C39JW444G — substance identity
- DailyMed: FDA labels for Cabozantinib — current prescribing information (label search)
- UniProt P35968 (KDR) — target protein
- UniProt Q12866 (MERTK) — target protein
- UniProt Q9NWH9 (SLTM) — target protein
- UniProt P08581 (MET) — target protein
- UniProt Q06418 (TYRO3) — target protein
- UniProt P30530 (AXL) — target protein
- FDA Adverse Event Reporting System (openFDA FAERS) — adverse-event signals, as aggregated by DrugCentral
- PharmGKB / CPIC — pharmacogenomic label annotations
How this page is built: methodology · editorial policy & corrections.
For research and educational use only — not medical advice. This page is compiled automatically from public databases. It is not written or reviewed by a clinician. Do not start, stop or change any treatment based on it; consult a qualified healthcare professional. Spotted an error? See our corrections policy or email hello@molforge.ai.